Kaushal Kalra

Dr. Kaushal Kalra


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2022 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
VGVikas Garg
Vikas Garg
SRSAMEER RASTOGI
SAMEER RASTOGI
KKKaushal Kalra
Kaushal Kalra
SBSandeep Bhoriwal
Sandeep Bhoriwal
ABAdarsh Barwad
Adarsh Barwad
SGShivanand Gamangatti
Shivanand Gamangatti

5 August 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
VTVineet Talwar
Vineet Talwar
KKKaushal Kalra
Kaushal Kalra
AKAkhil Kapoor
Akhil Kapoor
PDP. S. Dattatreya
P. S. Dattatreya
AJAmit Joshi
Amit Joshi
NLNilesh Lokeshwar
Nilesh Lokeshwar
The treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC) has transformed significantly with the advent of triplet therapy involving androgen deprivation therapy (ADT), docetaxel, and androgen receptor signalling inhibitors (ARSIs). While clinical guidelines increasingly support early intensification, real-world practice remains challenged by patient heterogeneity, evolving evidence, and limited consensus on treatment sequencing. This narrative review integrates evidence from landmark trials, clinical guidelines, and expert insights from oncologists managing mHSPC in India. Findings affirm that triplet therapy, particularly with darolutamide, improves survival in high-volume disease and underscores the need for personalized treatment based on disease burden, comorbidities, and genomic profiles. The review also highlights gaps in real-world data, sequencing strategies, and biomarker-driven therapy, reinforcing the need for precision medicine and locally relevant evidence to guide treatment. Ultimately, optimizing mHSPC management requires harmonizing guideline-based approaches with individualized, real-world decision making to improve patient outcomes.

1 January 2024 in Oncology Journal of India
Verified
Journal Article
Open access
SGSumedha Gupta
Sumedha Gupta
KKKaushal Kalra
Kaushal Kalra
DKDheer Singh Kalwaniya
Dheer Singh Kalwaniya
CACharanjeet Ahluwalia
Charanjeet Ahluwalia
Sarcoma of the breast represents a rare entity accounting for <1% of all breast tumors. Liposarcoma (LPS) of the breast is an exceedingly rare malignancy with an incidence of 0.3% of all breast sarcomas and myxoid LPS (MLPS), the second most common subtype of LPS, is even rarer in breast tissue. We present a notable case of MLPS affecting the breast of a 35-year-old male patient. The patient presented with a painless swelling in the left breast, which was subsequently diagnosed with MLPS through histopathological analysis following wide local excision. The tumor exhibited low mitotic count, clear resected margins, and positivity for S-100 on immunohistochemistry. Postoperative positron emission computerized tomography revealed no residual disease, and the patient received postoperative radiation therapy to minimize the risk of local recurrence. MLPS management requires a tailored approach, considering tumor size, location, and histological characteristics. Achieving negative margins through surgical resection remains crucial, with standardized definitions aiding in treatment consistency. The present case highlights the challenges in managing rare breast sarcomas and emphasizes the importance of a multidisciplinary approach to optimize patient outcomes.

2 August 2024 in Indian Journal of Gynecologic Oncology
Verified
Journal Article
Closed access
PDF file
SGSumedha Gupta
Sumedha Gupta
SASana Ahuja
Sana Ahuja
KKKaushal Kalra
Kaushal Kalra
AMArchana Mishra
Archana Mishra
DKDheer Singh Kalwaniya
Dheer Singh Kalwaniya